The AstraZeneca Plc unit, MedImmune, has entered into a three-year collaboration with the technology transfer arm of France’s National Institute of Health and Medical Research (Inserm) to research disease and potential drug candidates. ---Subscribe to MedNous to access this article--- Company News Research & University News
